Business
ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System
Patent strengthens ENvue’s IP position as it advances toward pediatric regulatory clearance and expanded clinical use TYLER, Texas--(BUSINESS WIRE)--
About this update from Envue Medical, Inc.
[{"type":"text","content":"\nPatent strengthens ENvue’s IP position as it advances toward pediatric regulatory clearance and expanded clinical use\n\n\n TYLER, Texas--(BUSINESS WIRE)--\nNanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical” or “ENvue”), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled “Insertion Device Positioning Guidance System,” further strengthens ENvue Medical’s intellectual property portfolio and reflects the Company’s ongoing commitment to innovation in feeding tube placement technologies.\n\n\nThis newly granted patent covers ENvue’s proprietary system and is designed to assist clinicians in guiding the insertion of feeding tubes in pediatric patients - a population that presents significant anatomical and procedural challenges. This proprietary system is intended to provide real-time navigational data during tube placement, supporting clinical decision-making and potentially reducing reliance on confirmatory imaging.\n\n\nIn the United States alone, approximately 400,000 preterm infants and a large population of additional pediatric patients, including those in intensive care, surgical recovery and chronic care undergo feeding tube placement annually.1-4 Combined, these high-risk groups account for over 1.5 million procedures per year, representing a single U.S. market opportunity of more than $150 million annually in capital systems and disposables5. ENvue’s newly granted patent strengthens its ability to serve this critical segment with real-time, precision-guided navigation.\n\n\n“We believe the addressable market for our pediatric navigation platform is substantial,” said Dr. Doron Besser, CEO of the Company. “Accordingly, this patent reflects our commitment to addressing this market opportunity by developing more precise, real-time enteral access solutions tailored to the needs of vulnerable patient populations. We continue to innovate with the goal of expanding clinical capabilities and meeting unmet needs in the field of enteral access.”\n\n\nAs part of its broader product development strategy, ENvue Medical is preparing to pursue U.S. Food and Drug Administration (FDA) 510(k) clearance for the pediatric use of i...